25 April 2024
Organised by:
SCI’s Fine Chemicals Group
SCI, London, UK
Peptides as a drug modality offer several advantages over both traditional small molecules and biologics including improved tissue penetration, simpler more modular design characteristics, accessing previously intractable targets and reduced immunogenic risks. The advancement of peptides as therapeutics has been aided by the development of peptide drug conjugates, and this event brings together world class and cutting edge scientists in the fields of peptide and peptide macrocyclic drug and drug conjugate research. The event will give insights into the challenges posed and also the potential for these drugs to make a real world impact, and to interact with active researchers.
This event will be of interest to academic and industrial scientists, interested in learning the latest innovations in the field of peptide and peptide macrocyclic drug and drug conjugate developments.
The full programme will be confirmed in due course.
SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.
For further information and prices, please email conferences@soci.org.
SCI
14/15 Belgrave Square
London
SW1X 8PS
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
SCI Members attending this meeting are able to claim CPD points.